Senesco Technologies has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/IIa clinical study of SNS01-T, its lead therapeutic candidate for the treatment of multiple myeloma. Criterium is a full-service, global CRO. The Senesco team recently met with counterparts at Criterium to finalize the operational plans for the conduct and analysis of this open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administe...